ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Biopharmaceutical and Bio-CDMO Market Research Report 2025
Published Date: June 2025
|
Report Code: QYRE-Auto-29K17677
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Biopharmaceutical and Bio CDMO Market Research Report 2024
BUY CHAPTERS

Global Biopharmaceutical and Bio-CDMO Market Research Report 2025

Code: QYRE-Auto-29K17677
Report
June 2025
Pages:93
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Samsung Biologics
FUJIFILM Diosynth Biotechnologies
Recipharm
Thermo Fisher Scientific
AGC Biologics
Rentschler Biopharma
KBI Biopharma
Siegfried
Aenova Group
GenScript
ProBioGen
Northway Biotech
3P Biopharmaceuticals
Boehringer Ingelheim
Catalent
Lonza
Wuxi Biologics

Biopharmaceutical and Bio-CDMO Market Size

The global market for Biopharmaceutical and Bio-CDMO was valued at US$ 28160 million in the year 2024 and is projected to reach a revised size of US$ 66050 million by 2031, growing at a CAGR of 13.1% during the forecast period.

Biopharmaceutical and Bio-CDMO Market

Biopharmaceutical and Bio-CDMO Market

Biopharmaceutical Contract Development and Manufacturing Organizations (CDMOs) are companies that provide comprehensive services for the development and manufacturing of biopharmaceutical products. These organizations play a crucial role in the biopharmaceutical industry by offering a range of services to biotech and pharmaceutical companies, allowing them to outsource various stages of the drug development and manufacturing process.
Increasing Demand for Biologics: The rising demand for biopharmaceuticals, including monoclonal antibodies, recombinant proteins, and gene therapies, is a significant driver. Biologics are increasingly becoming a focus for drug development due to their effectiveness in treating various diseases.
Cost-Effective Outsourcing: Outsourcing to CDMOs allows pharmaceutical and biotech companies to reduce capital expenditures, mitigate risks, and achieve cost savings. CDMOs offer specialized facilities and expertise, allowing clients to avoid the need for extensive in-house infrastructure.
Strategic Partnerships and Collaborations: Pharmaceutical and biotech companies increasingly engage in strategic partnerships with CDMOs to access specialized capabilities, share development risks, and benefit from the CDMO's expertise in specific technologies or therapeutic areas.
To meet the growing demand for biopharmaceuticals, CDMOs are investing in expanding their biomanufacturing capacities. This includes the construction of new facilities and the acquisition of advanced technologies to increase production capabilities.
The increasing interest and investment in cell and gene therapies have led to a rise in demand for CDMOs offering services in this area. Companies are seeking expertise in cell line development, viral vector production, and other specialized services related to advanced therapies.
Biopharmaceutical CDMOs are expanding their global presence to cater to the needs of a geographically diverse client base. This includes establishing facilities in key regions and forming strategic partnerships to enhance their global reach.
CDMOs are expanding their service offerings to provide integrated solutions covering the entire biopharmaceutical development and manufacturing lifecycle. This integrated approach aims to streamline processes and accelerate time to market for clients.
This report aims to provide a comprehensive presentation of the global market for Biopharmaceutical and Bio-CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biopharmaceutical and Bio-CDMO.
The Biopharmaceutical and Bio-CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Biopharmaceutical and Bio-CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biopharmaceutical and Bio-CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Biopharmaceutical and Bio-CDMO Market Report

Report Metric Details
Report Name Biopharmaceutical and Bio-CDMO Market
Accounted market size in year US$ 28160 million
Forecasted market size in 2031 US$ 66050 million
CAGR 13.1%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Cell and Gene Therapies
  • Antibodies
  • Vaccines
  • Other
Segment by Application
  • SMBs
  • Large Companies
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi Biologics, Recipharm, Thermo Fisher Scientific, AGC Biologics, Rentschler Biopharma, KBI Biopharma, Siegfried, Aenova Group, GenScript, ProBioGen, Northway Biotech, 3P Biopharmaceuticals
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Biopharmaceutical and Bio-CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Biopharmaceutical and Bio-CDMO Market growing?

Ans: The Biopharmaceutical and Bio-CDMO Market witnessing a CAGR of 13.1% during the forecast period 2025-2031.

What is the Biopharmaceutical and Bio-CDMO Market size in 2031?

Ans: The Biopharmaceutical and Bio-CDMO Market size in 2031 will be US$ 66050 million.

Who are the main players in the Biopharmaceutical and Bio-CDMO Market report?

Ans: The main players in the Biopharmaceutical and Bio-CDMO Market are Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi Biologics, Recipharm, Thermo Fisher Scientific, AGC Biologics, Rentschler Biopharma, KBI Biopharma, Siegfried, Aenova Group, GenScript, ProBioGen, Northway Biotech, 3P Biopharmaceuticals

What are the Application segmentation covered in the Biopharmaceutical and Bio-CDMO Market report?

Ans: The Applications covered in the Biopharmaceutical and Bio-CDMO Market report are SMBs, Large Companies

What are the Type segmentation covered in the Biopharmaceutical and Bio-CDMO Market report?

Ans: The Types covered in the Biopharmaceutical and Bio-CDMO Market report are Cell and Gene Therapies, Antibodies, Vaccines, Other

Recommended Reports

CDMO Services Markets

Biopharma Outsourcing

Packaging and Supply

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biopharmaceutical and Bio-CDMO Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Cell and Gene Therapies
1.2.3 Antibodies
1.2.4 Vaccines
1.2.5 Other
1.3 Market by Application
1.3.1 Global Biopharmaceutical and Bio-CDMO Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 SMBs
1.3.3 Large Companies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biopharmaceutical and Bio-CDMO Market Perspective (2020-2031)
2.2 Global Biopharmaceutical and Bio-CDMO Growth Trends by Region
2.2.1 Global Biopharmaceutical and Bio-CDMO Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Biopharmaceutical and Bio-CDMO Historic Market Size by Region (2020-2025)
2.2.3 Biopharmaceutical and Bio-CDMO Forecasted Market Size by Region (2026-2031)
2.3 Biopharmaceutical and Bio-CDMO Market Dynamics
2.3.1 Biopharmaceutical and Bio-CDMO Industry Trends
2.3.2 Biopharmaceutical and Bio-CDMO Market Drivers
2.3.3 Biopharmaceutical and Bio-CDMO Market Challenges
2.3.4 Biopharmaceutical and Bio-CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biopharmaceutical and Bio-CDMO Players by Revenue
3.1.1 Global Top Biopharmaceutical and Bio-CDMO Players by Revenue (2020-2025)
3.1.2 Global Biopharmaceutical and Bio-CDMO Revenue Market Share by Players (2020-2025)
3.2 Global Top Biopharmaceutical and Bio-CDMO Players by Company Type and Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Biopharmaceutical and Bio-CDMO Revenue
3.4 Global Biopharmaceutical and Bio-CDMO Market Concentration Ratio
3.4.1 Global Biopharmaceutical and Bio-CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biopharmaceutical and Bio-CDMO Revenue in 2024
3.5 Global Key Players of Biopharmaceutical and Bio-CDMO Head office and Area Served
3.6 Global Key Players of Biopharmaceutical and Bio-CDMO, Product and Application
3.7 Global Key Players of Biopharmaceutical and Bio-CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Biopharmaceutical and Bio-CDMO Breakdown Data by Type
4.1 Global Biopharmaceutical and Bio-CDMO Historic Market Size by Type (2020-2025)
4.2 Global Biopharmaceutical and Bio-CDMO Forecasted Market Size by Type (2026-2031)
5 Biopharmaceutical and Bio-CDMO Breakdown Data by Application
5.1 Global Biopharmaceutical and Bio-CDMO Historic Market Size by Application (2020-2025)
5.2 Global Biopharmaceutical and Bio-CDMO Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Biopharmaceutical and Bio-CDMO Market Size (2020-2031)
6.2 North America Biopharmaceutical and Bio-CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Biopharmaceutical and Bio-CDMO Market Size by Country (2020-2025)
6.4 North America Biopharmaceutical and Bio-CDMO Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biopharmaceutical and Bio-CDMO Market Size (2020-2031)
7.2 Europe Biopharmaceutical and Bio-CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Biopharmaceutical and Bio-CDMO Market Size by Country (2020-2025)
7.4 Europe Biopharmaceutical and Bio-CDMO Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Biopharmaceutical and Bio-CDMO Market Size (2020-2031)
8.2 Asia-Pacific Biopharmaceutical and Bio-CDMO Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Biopharmaceutical and Bio-CDMO Market Size by Region (2020-2025)
8.4 Asia-Pacific Biopharmaceutical and Bio-CDMO Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Biopharmaceutical and Bio-CDMO Market Size (2020-2031)
9.2 Latin America Biopharmaceutical and Bio-CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Biopharmaceutical and Bio-CDMO Market Size by Country (2020-2025)
9.4 Latin America Biopharmaceutical and Bio-CDMO Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biopharmaceutical and Bio-CDMO Market Size (2020-2031)
10.2 Middle East & Africa Biopharmaceutical and Bio-CDMO Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Biopharmaceutical and Bio-CDMO Market Size by Country (2020-2025)
10.4 Middle East & Africa Biopharmaceutical and Bio-CDMO Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza
11.1.1 Lonza Company Details
11.1.2 Lonza Business Overview
11.1.3 Lonza Biopharmaceutical and Bio-CDMO Introduction
11.1.4 Lonza Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025)
11.1.5 Lonza Recent Development
11.2 Catalent
11.2.1 Catalent Company Details
11.2.2 Catalent Business Overview
11.2.3 Catalent Biopharmaceutical and Bio-CDMO Introduction
11.2.4 Catalent Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025)
11.2.5 Catalent Recent Development
11.3 Samsung Biologics
11.3.1 Samsung Biologics Company Details
11.3.2 Samsung Biologics Business Overview
11.3.3 Samsung Biologics Biopharmaceutical and Bio-CDMO Introduction
11.3.4 Samsung Biologics Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025)
11.3.5 Samsung Biologics Recent Development
11.4 FUJIFILM Diosynth Biotechnologies
11.4.1 FUJIFILM Diosynth Biotechnologies Company Details
11.4.2 FUJIFILM Diosynth Biotechnologies Business Overview
11.4.3 FUJIFILM Diosynth Biotechnologies Biopharmaceutical and Bio-CDMO Introduction
11.4.4 FUJIFILM Diosynth Biotechnologies Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025)
11.4.5 FUJIFILM Diosynth Biotechnologies Recent Development
11.5 Boehringer Ingelheim
11.5.1 Boehringer Ingelheim Company Details
11.5.2 Boehringer Ingelheim Business Overview
11.5.3 Boehringer Ingelheim Biopharmaceutical and Bio-CDMO Introduction
11.5.4 Boehringer Ingelheim Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025)
11.5.5 Boehringer Ingelheim Recent Development
11.6 WuXi Biologics
11.6.1 WuXi Biologics Company Details
11.6.2 WuXi Biologics Business Overview
11.6.3 WuXi Biologics Biopharmaceutical and Bio-CDMO Introduction
11.6.4 WuXi Biologics Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025)
11.6.5 WuXi Biologics Recent Development
11.7 Recipharm
11.7.1 Recipharm Company Details
11.7.2 Recipharm Business Overview
11.7.3 Recipharm Biopharmaceutical and Bio-CDMO Introduction
11.7.4 Recipharm Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025)
11.7.5 Recipharm Recent Development
11.8 Thermo Fisher Scientific
11.8.1 Thermo Fisher Scientific Company Details
11.8.2 Thermo Fisher Scientific Business Overview
11.8.3 Thermo Fisher Scientific Biopharmaceutical and Bio-CDMO Introduction
11.8.4 Thermo Fisher Scientific Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025)
11.8.5 Thermo Fisher Scientific Recent Development
11.9 AGC Biologics
11.9.1 AGC Biologics Company Details
11.9.2 AGC Biologics Business Overview
11.9.3 AGC Biologics Biopharmaceutical and Bio-CDMO Introduction
11.9.4 AGC Biologics Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025)
11.9.5 AGC Biologics Recent Development
11.10 Rentschler Biopharma
11.10.1 Rentschler Biopharma Company Details
11.10.2 Rentschler Biopharma Business Overview
11.10.3 Rentschler Biopharma Biopharmaceutical and Bio-CDMO Introduction
11.10.4 Rentschler Biopharma Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025)
11.10.5 Rentschler Biopharma Recent Development
11.11 KBI Biopharma
11.11.1 KBI Biopharma Company Details
11.11.2 KBI Biopharma Business Overview
11.11.3 KBI Biopharma Biopharmaceutical and Bio-CDMO Introduction
11.11.4 KBI Biopharma Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025)
11.11.5 KBI Biopharma Recent Development
11.12 Siegfried
11.12.1 Siegfried Company Details
11.12.2 Siegfried Business Overview
11.12.3 Siegfried Biopharmaceutical and Bio-CDMO Introduction
11.12.4 Siegfried Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025)
11.12.5 Siegfried Recent Development
11.13 Aenova Group
11.13.1 Aenova Group Company Details
11.13.2 Aenova Group Business Overview
11.13.3 Aenova Group Biopharmaceutical and Bio-CDMO Introduction
11.13.4 Aenova Group Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025)
11.13.5 Aenova Group Recent Development
11.14 GenScript
11.14.1 GenScript Company Details
11.14.2 GenScript Business Overview
11.14.3 GenScript Biopharmaceutical and Bio-CDMO Introduction
11.14.4 GenScript Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025)
11.14.5 GenScript Recent Development
11.15 ProBioGen
11.15.1 ProBioGen Company Details
11.15.2 ProBioGen Business Overview
11.15.3 ProBioGen Biopharmaceutical and Bio-CDMO Introduction
11.15.4 ProBioGen Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025)
11.15.5 ProBioGen Recent Development
11.16 Northway Biotech
11.16.1 Northway Biotech Company Details
11.16.2 Northway Biotech Business Overview
11.16.3 Northway Biotech Biopharmaceutical and Bio-CDMO Introduction
11.16.4 Northway Biotech Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025)
11.16.5 Northway Biotech Recent Development
11.17 3P Biopharmaceuticals
11.17.1 3P Biopharmaceuticals Company Details
11.17.2 3P Biopharmaceuticals Business Overview
11.17.3 3P Biopharmaceuticals Biopharmaceutical and Bio-CDMO Introduction
11.17.4 3P Biopharmaceuticals Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025)
11.17.5 3P Biopharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Samsung Biologics
FUJIFILM Diosynth Biotechnologies
Recipharm
Thermo Fisher Scientific
AGC Biologics
Rentschler Biopharma
KBI Biopharma
Siegfried
Aenova Group
GenScript
ProBioGen
Northway Biotech
3P Biopharmaceuticals
Boehringer Ingelheim
Catalent
Lonza
Wuxi Biologics
List of Tables
 Table 1. Global Biopharmaceutical and Bio-CDMO Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Cell and Gene Therapies
 Table 3. Key Players of Antibodies
 Table 4. Key Players of Vaccines
 Table 5. Key Players of Other
 Table 6. Global Biopharmaceutical and Bio-CDMO Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 7. Global Biopharmaceutical and Bio-CDMO Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 8. Global Biopharmaceutical and Bio-CDMO Market Size by Region (2020-2025) & (US$ Million)
 Table 9. Global Biopharmaceutical and Bio-CDMO Market Share by Region (2020-2025)
 Table 10. Global Biopharmaceutical and Bio-CDMO Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 11. Global Biopharmaceutical and Bio-CDMO Market Share by Region (2026-2031)
 Table 12. Biopharmaceutical and Bio-CDMO Market Trends
 Table 13. Biopharmaceutical and Bio-CDMO Market Drivers
 Table 14. Biopharmaceutical and Bio-CDMO Market Challenges
 Table 15. Biopharmaceutical and Bio-CDMO Market Restraints
 Table 16. Global Biopharmaceutical and Bio-CDMO Revenue by Players (2020-2025) & (US$ Million)
 Table 17. Global Biopharmaceutical and Bio-CDMO Market Share by Players (2020-2025)
 Table 18. Global Top Biopharmaceutical and Bio-CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biopharmaceutical and Bio-CDMO as of 2024)
 Table 19. Ranking of Global Top Biopharmaceutical and Bio-CDMO Companies by Revenue (US$ Million) in 2024
 Table 20. Global 5 Largest Players Market Share by Biopharmaceutical and Bio-CDMO Revenue (CR5 and HHI) & (2020-2025)
 Table 21. Global Key Players of Biopharmaceutical and Bio-CDMO, Headquarters and Area Served
 Table 22. Global Key Players of Biopharmaceutical and Bio-CDMO, Product and Application
 Table 23. Global Key Players of Biopharmaceutical and Bio-CDMO, Date of Enter into This Industry
 Table 24. Mergers & Acquisitions, Expansion Plans
 Table 25. Global Biopharmaceutical and Bio-CDMO Market Size by Type (2020-2025) & (US$ Million)
 Table 26. Global Biopharmaceutical and Bio-CDMO Revenue Market Share by Type (2020-2025)
 Table 27. Global Biopharmaceutical and Bio-CDMO Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 28. Global Biopharmaceutical and Bio-CDMO Revenue Market Share by Type (2026-2031)
 Table 29. Global Biopharmaceutical and Bio-CDMO Market Size by Application (2020-2025) & (US$ Million)
 Table 30. Global Biopharmaceutical and Bio-CDMO Revenue Market Share by Application (2020-2025)
 Table 31. Global Biopharmaceutical and Bio-CDMO Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 32. Global Biopharmaceutical and Bio-CDMO Revenue Market Share by Application (2026-2031)
 Table 33. North America Biopharmaceutical and Bio-CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 34. North America Biopharmaceutical and Bio-CDMO Market Size by Country (2020-2025) & (US$ Million)
 Table 35. North America Biopharmaceutical and Bio-CDMO Market Size by Country (2026-2031) & (US$ Million)
 Table 36. Europe Biopharmaceutical and Bio-CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 37. Europe Biopharmaceutical and Bio-CDMO Market Size by Country (2020-2025) & (US$ Million)
 Table 38. Europe Biopharmaceutical and Bio-CDMO Market Size by Country (2026-2031) & (US$ Million)
 Table 39. Asia-Pacific Biopharmaceutical and Bio-CDMO Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 40. Asia-Pacific Biopharmaceutical and Bio-CDMO Market Size by Region (2020-2025) & (US$ Million)
 Table 41. Asia-Pacific Biopharmaceutical and Bio-CDMO Market Size by Region (2026-2031) & (US$ Million)
 Table 42. Latin America Biopharmaceutical and Bio-CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 43. Latin America Biopharmaceutical and Bio-CDMO Market Size by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Biopharmaceutical and Bio-CDMO Market Size by Country (2026-2031) & (US$ Million)
 Table 45. Middle East & Africa Biopharmaceutical and Bio-CDMO Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 46. Middle East & Africa Biopharmaceutical and Bio-CDMO Market Size by Country (2020-2025) & (US$ Million)
 Table 47. Middle East & Africa Biopharmaceutical and Bio-CDMO Market Size by Country (2026-2031) & (US$ Million)
 Table 48. Lonza Company Details
 Table 49. Lonza Business Overview
 Table 50. Lonza Biopharmaceutical and Bio-CDMO Product
 Table 51. Lonza Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025) & (US$ Million)
 Table 52. Lonza Recent Development
 Table 53. Catalent Company Details
 Table 54. Catalent Business Overview
 Table 55. Catalent Biopharmaceutical and Bio-CDMO Product
 Table 56. Catalent Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025) & (US$ Million)
 Table 57. Catalent Recent Development
 Table 58. Samsung Biologics Company Details
 Table 59. Samsung Biologics Business Overview
 Table 60. Samsung Biologics Biopharmaceutical and Bio-CDMO Product
 Table 61. Samsung Biologics Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025) & (US$ Million)
 Table 62. Samsung Biologics Recent Development
 Table 63. FUJIFILM Diosynth Biotechnologies Company Details
 Table 64. FUJIFILM Diosynth Biotechnologies Business Overview
 Table 65. FUJIFILM Diosynth Biotechnologies Biopharmaceutical and Bio-CDMO Product
 Table 66. FUJIFILM Diosynth Biotechnologies Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025) & (US$ Million)
 Table 67. FUJIFILM Diosynth Biotechnologies Recent Development
 Table 68. Boehringer Ingelheim Company Details
 Table 69. Boehringer Ingelheim Business Overview
 Table 70. Boehringer Ingelheim Biopharmaceutical and Bio-CDMO Product
 Table 71. Boehringer Ingelheim Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025) & (US$ Million)
 Table 72. Boehringer Ingelheim Recent Development
 Table 73. WuXi Biologics Company Details
 Table 74. WuXi Biologics Business Overview
 Table 75. WuXi Biologics Biopharmaceutical and Bio-CDMO Product
 Table 76. WuXi Biologics Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025) & (US$ Million)
 Table 77. WuXi Biologics Recent Development
 Table 78. Recipharm Company Details
 Table 79. Recipharm Business Overview
 Table 80. Recipharm Biopharmaceutical and Bio-CDMO Product
 Table 81. Recipharm Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025) & (US$ Million)
 Table 82. Recipharm Recent Development
 Table 83. Thermo Fisher Scientific Company Details
 Table 84. Thermo Fisher Scientific Business Overview
 Table 85. Thermo Fisher Scientific Biopharmaceutical and Bio-CDMO Product
 Table 86. Thermo Fisher Scientific Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025) & (US$ Million)
 Table 87. Thermo Fisher Scientific Recent Development
 Table 88. AGC Biologics Company Details
 Table 89. AGC Biologics Business Overview
 Table 90. AGC Biologics Biopharmaceutical and Bio-CDMO Product
 Table 91. AGC Biologics Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025) & (US$ Million)
 Table 92. AGC Biologics Recent Development
 Table 93. Rentschler Biopharma Company Details
 Table 94. Rentschler Biopharma Business Overview
 Table 95. Rentschler Biopharma Biopharmaceutical and Bio-CDMO Product
 Table 96. Rentschler Biopharma Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025) & (US$ Million)
 Table 97. Rentschler Biopharma Recent Development
 Table 98. KBI Biopharma Company Details
 Table 99. KBI Biopharma Business Overview
 Table 100. KBI Biopharma Biopharmaceutical and Bio-CDMO Product
 Table 101. KBI Biopharma Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025) & (US$ Million)
 Table 102. KBI Biopharma Recent Development
 Table 103. Siegfried Company Details
 Table 104. Siegfried Business Overview
 Table 105. Siegfried Biopharmaceutical and Bio-CDMO Product
 Table 106. Siegfried Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025) & (US$ Million)
 Table 107. Siegfried Recent Development
 Table 108. Aenova Group Company Details
 Table 109. Aenova Group Business Overview
 Table 110. Aenova Group Biopharmaceutical and Bio-CDMO Product
 Table 111. Aenova Group Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025) & (US$ Million)
 Table 112. Aenova Group Recent Development
 Table 113. GenScript Company Details
 Table 114. GenScript Business Overview
 Table 115. GenScript Biopharmaceutical and Bio-CDMO Product
 Table 116. GenScript Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025) & (US$ Million)
 Table 117. GenScript Recent Development
 Table 118. ProBioGen Company Details
 Table 119. ProBioGen Business Overview
 Table 120. ProBioGen Biopharmaceutical and Bio-CDMO Product
 Table 121. ProBioGen Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025) & (US$ Million)
 Table 122. ProBioGen Recent Development
 Table 123. Northway Biotech Company Details
 Table 124. Northway Biotech Business Overview
 Table 125. Northway Biotech Biopharmaceutical and Bio-CDMO Product
 Table 126. Northway Biotech Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025) & (US$ Million)
 Table 127. Northway Biotech Recent Development
 Table 128. 3P Biopharmaceuticals Company Details
 Table 129. 3P Biopharmaceuticals Business Overview
 Table 130. 3P Biopharmaceuticals Biopharmaceutical and Bio-CDMO Product
 Table 131. 3P Biopharmaceuticals Revenue in Biopharmaceutical and Bio-CDMO Business (2020-2025) & (US$ Million)
 Table 132. 3P Biopharmaceuticals Recent Development
 Table 133. Research Programs/Design for This Report
 Table 134. Key Data Information from Secondary Sources
 Table 135. Key Data Information from Primary Sources
 Table 136. Authors List of This Report


List of Figures
 Figure 1. Biopharmaceutical and Bio-CDMO Picture
 Figure 2. Global Biopharmaceutical and Bio-CDMO Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Biopharmaceutical and Bio-CDMO Market Share by Type: 2024 VS 2031
 Figure 4. Cell and Gene Therapies Features
 Figure 5. Antibodies Features
 Figure 6. Vaccines Features
 Figure 7. Other Features
 Figure 8. Global Biopharmaceutical and Bio-CDMO Market Size by Application (2020-2031) & (US$ Million)
 Figure 9. Global Biopharmaceutical and Bio-CDMO Market Share by Application: 2024 VS 2031
 Figure 10. SMBs Case Studies
 Figure 11. Large Companies Case Studies
 Figure 12. Biopharmaceutical and Bio-CDMO Report Years Considered
 Figure 13. Global Biopharmaceutical and Bio-CDMO Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 14. Global Biopharmaceutical and Bio-CDMO Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global Biopharmaceutical and Bio-CDMO Market Share by Region: 2024 VS 2031
 Figure 16. Global Biopharmaceutical and Bio-CDMO Market Share by Players in 2024
 Figure 17. Global Biopharmaceutical and Bio-CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
 Figure 18. The Top 10 and 5 Players Market Share by Biopharmaceutical and Bio-CDMO Revenue in 2024
 Figure 19. North America Biopharmaceutical and Bio-CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 20. North America Biopharmaceutical and Bio-CDMO Market Share by Country (2020-2031)
 Figure 21. United States Biopharmaceutical and Bio-CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Canada Biopharmaceutical and Bio-CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 23. Europe Biopharmaceutical and Bio-CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. Europe Biopharmaceutical and Bio-CDMO Market Share by Country (2020-2031)
 Figure 25. Germany Biopharmaceutical and Bio-CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. France Biopharmaceutical and Bio-CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. U.K. Biopharmaceutical and Bio-CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Italy Biopharmaceutical and Bio-CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Russia Biopharmaceutical and Bio-CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Nordic Countries Biopharmaceutical and Bio-CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 31. Asia-Pacific Biopharmaceutical and Bio-CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Asia-Pacific Biopharmaceutical and Bio-CDMO Market Share by Region (2020-2031)
 Figure 33. China Biopharmaceutical and Bio-CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Japan Biopharmaceutical and Bio-CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. South Korea Biopharmaceutical and Bio-CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Southeast Asia Biopharmaceutical and Bio-CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. India Biopharmaceutical and Bio-CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Australia Biopharmaceutical and Bio-CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 39. Latin America Biopharmaceutical and Bio-CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Latin America Biopharmaceutical and Bio-CDMO Market Share by Country (2020-2031)
 Figure 41. Mexico Biopharmaceutical and Bio-CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Brazil Biopharmaceutical and Bio-CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 43. Middle East & Africa Biopharmaceutical and Bio-CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Middle East & Africa Biopharmaceutical and Bio-CDMO Market Share by Country (2020-2031)
 Figure 45. Turkey Biopharmaceutical and Bio-CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Saudi Arabia Biopharmaceutical and Bio-CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 47. UAE Biopharmaceutical and Bio-CDMO Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 48. Lonza Revenue Growth Rate in Biopharmaceutical and Bio-CDMO Business (2020-2025)
 Figure 49. Catalent Revenue Growth Rate in Biopharmaceutical and Bio-CDMO Business (2020-2025)
 Figure 50. Samsung Biologics Revenue Growth Rate in Biopharmaceutical and Bio-CDMO Business (2020-2025)
 Figure 51. FUJIFILM Diosynth Biotechnologies Revenue Growth Rate in Biopharmaceutical and Bio-CDMO Business (2020-2025)
 Figure 52. Boehringer Ingelheim Revenue Growth Rate in Biopharmaceutical and Bio-CDMO Business (2020-2025)
 Figure 53. WuXi Biologics Revenue Growth Rate in Biopharmaceutical and Bio-CDMO Business (2020-2025)
 Figure 54. Recipharm Revenue Growth Rate in Biopharmaceutical and Bio-CDMO Business (2020-2025)
 Figure 55. Thermo Fisher Scientific Revenue Growth Rate in Biopharmaceutical and Bio-CDMO Business (2020-2025)
 Figure 56. AGC Biologics Revenue Growth Rate in Biopharmaceutical and Bio-CDMO Business (2020-2025)
 Figure 57. Rentschler Biopharma Revenue Growth Rate in Biopharmaceutical and Bio-CDMO Business (2020-2025)
 Figure 58. KBI Biopharma Revenue Growth Rate in Biopharmaceutical and Bio-CDMO Business (2020-2025)
 Figure 59. Siegfried Revenue Growth Rate in Biopharmaceutical and Bio-CDMO Business (2020-2025)
 Figure 60. Aenova Group Revenue Growth Rate in Biopharmaceutical and Bio-CDMO Business (2020-2025)
 Figure 61. GenScript Revenue Growth Rate in Biopharmaceutical and Bio-CDMO Business (2020-2025)
 Figure 62. ProBioGen Revenue Growth Rate in Biopharmaceutical and Bio-CDMO Business (2020-2025)
 Figure 63. Northway Biotech Revenue Growth Rate in Biopharmaceutical and Bio-CDMO Business (2020-2025)
 Figure 64. 3P Biopharmaceuticals Revenue Growth Rate in Biopharmaceutical and Bio-CDMO Business (2020-2025)
 Figure 65. Bottom-up and Top-down Approaches for This Report
 Figure 66. Data Triangulation
 Figure 67. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

Global Biopharmaceutical CDMO Market Research Report 2025
Global Biopharmaceutical CDMO Service Market Research Report 2024
Global Bio Contract Development and Manufacturing Organizations CDMOs Market Insights Forecast to 2030
Global Biological Drug CDMO Market Research Report 2024
Biologics CDMO Market
Global Cell and Gene Therapy CDMO Services Market Research Report 2024
Global Full Service CDMO Market Research Report 2024
Global Contract Dose Manufacturing Market Insights Forecast to 2030
Global Chemical CDMO Market Research Report 2024
Global Pharmaceutical Contract Development and Manufacturing Organization Market Research Report 2025
Global Biologics CDMO Services Market Research Report 2024
Global Cell Therapy CDMO Services Market Research Report 2025
Global Pharmaceutical CDMO Market Research Report 2025
Pharmaceutical CMO and CDMO Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Microbiome CDMO Market Research Report 2024
Pharmaceutical CDMO Solution Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Small Molecule Drug CDMO Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Viral Vector Manufacturing CDMO Services Market Research Report 2024
Global Plasmid DNA CDMO Service Market Research Report 2024
Global Antibody Drug CDMO Service Market Research Report 2024

RELATED REPORTS

Global Pharma and Healthcare Social Media Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-14Y6812
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Food Additives Testing Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-34O3983
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Gabapentin API Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-9V17601
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Global Electronic Informed Consent Market Research Report 2025

120 Pages
Type: Report
Code: QYRE-Auto-22C17047
Fri Sep 12 00:00:00 UTC 2025

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions